Page 7 - Biocon

Biocon gets EMA's nod to make biosimilar cancer drug at Bengaluru

Bevacizumab is used to treat colon and rectal cancer, cervical cancer etc

Biocon searches for partner to test generic Wegovy, Ozempic in China

Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide

Biocon signs licensing, supply deal for obesity drug in South Korea

Bengaluru-based company announces 'strategic partnership' with Handok

Stocks to Watch, May 22: Apollo Tyres, Biocon, Gulf Oil, Ircon Int'l

European markets closed on a negative note, with Germany's DAX falling 0.22 per cent and the UK's FTSE dropping 0.09 per cent

Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains

Peter Bains discusses their efforts to gain market share in key regions, the impact of lower active pharmaceutical ingredient prices, and growth plans for biosimilars and generics

Biocon Biologics announces getting US FDA approval for eye treatment drug

Company says approval is a 'significant milestone' and marks entry in new therapeutic area in the US

Biocon Q4 results: Net profit falls 57% to Rs 136 crore; revenue up 0.94%

Biocon has re-appointed Kiran Mazumdar Shaw as an Executive Director of the company for a further period of 5 years starting April 2025

Biocon Q4 results: Profit drops 57% to Rs 135 crore; revenue up 4%

Biocon Q4FY24 results: The company board has recommended a final dividend at the rate of 10 per cent i.e. Re. 0.50 per equity share

Q4 FY24 results: RVNL, MOIL, Biocon among 84 firms to post earnings today

Q4 FY24 company results: Dixon Technologies, Jindal Stainless, Power Finance Corporation, Thomas Cook will also release their financial results

Nifty bias to remain negative till it breaches 22,500, says Ajit Mishra

Nifty50 outlook: On the downside, the 21,850-22,150 zone is anticipated to provide support. Traders are advised to maintain caution

Syngene Q4 results: Net profit up 6% to Rs 189 cr, revenue declines 8%

Syngene International shares ended the day's trade on BSE at Rs 694.2 apiece, down one per cent

Biocon signs deal with Biomm SA to commercialise diabetes drug in Brazil

Biomm SA develops and commercialises complex biotech and biosimilar drug products

Biocon partners Biomm SA to commercialise it's diabetes drug in Brazil

Biotechnology firm Biocon on Wednesday said it has tied up with Brazil-based Biomm SA for the commercialisation of its diabetes drug in the Latin American nation. Under the terms of the agreement, Biocon will undertake the development, manufacturing and supply of Semaglutide (gOzempic), and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market. Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima. "Our partnership with Biomm marks another important step forward in our strategy to expand our global footprint beyond the US and Europe for Peptides," Biocon CEO and MD Siddharth Mittal said in a statement. This is also in line with the growth strategy of bringing to market a portfolio of complex, GLP-1 drug-device combination products, he added. "We are confident that our collaboration with Biomm will provide patients in Brazil, who are livi

Biocon leads India's push into anti-obesity drugs as patents lapse

The company, helmed by Kiran Mazumdar Shaw, is leading the charge among Indian drugmakers - the world's largest supplier of generic medicines - as they race to grab a slice of the obesity drugs market

Stocks to watch: Maruti Suzuki, NHPC, Dr Reddy's, Biocon, REC, GOCL Corp

Stocks to watch on March 28: Adani Power has awarded a contract valued at Rs 4,000 crore to Bharat Heavy Electricals for the establishment of a thermal power plant in Chhattisgarh

Biocon slips 5% on plan to sell branded formulation biz to Eris

Shares of Biocon slipped 5 per cent to Rs 254.15 on the BSE in Friday's intra-day trade as the company's unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore

The deal would enable Eris' entry into the Rs 3k cr injectables market, and it would become one of major players in the insulins segment with the acquisition of Biocon Biologic's Basalog and Insugen

Biocon to sell branded formulations biz to Eris Lifesciences for $150 mn

Biocon had earlier sold its dermatology and nephrology branded formulation businesses to Eris for Rs 350 crore in November last year

Biocon Biologics gets green light to launch Yesafili biosimilar in Canada

Under the agreement, Biocon Biologics will launch Yesafili no later than July 1, 2025. Health Canada had granted tentative approval for Yesafili in March 2023

Stocks to watch: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T

Stocks to watch on March 1, 2024: L&T has commissioned its first hydrogen electrolyser at the green hydrogen plant at Hazira, Gujarat